---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-012596"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-02-17T23:59:59+00:00"
generated_at: "2026-06-19T08:10:15.588095+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics reports Phase 1 briquilimab data: all 12 patients engrafted; appoints Vishal Kapoor to board

## Summary
- Appointed Vishal Kapoor to board effective Feb 16, 2023; he is Partner at Avego Management and received option for 109,383 shares at $1.83.
- Phase 1 briquilimab data: 12/12 AML patients achieved neutrophil engraftment at median 19 days; no briquilimab-related SAEs.
- 12 patients at Stanford treated outpatient; all discharged same day (zero inpatient days); mean inpatient stay over first 100 days was 4 days.
- Addition of briquilimab to conditioning regimen does not appear to increase GVHD incidence relative to published rates.

## SEC filing metadata
- accession: 0001213900-23-012596
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/0001213900-23-012596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/ea173877-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-012596
- JSON: https://secwatch.observer/filing/0001213900-23-012596.json
- Plain text: https://secwatch.observer/filing/0001213900-23-012596.txt

## Key facts
- Executive change
  Vishal Kapoor was appointed as Class I Director at Jasper Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: Effective February 16, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Vishal Kapoor as a Class I director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/0001213900-23-012596-index.htm
- Governance Changes
  Jasper Therapeutics, Inc.: Adopted third amended and restated bylaws to address universal proxy rules and enhance disclosure requirements for director nominations and business proposals by stockholders (effective 2023-02-16).
  - Change: bylaw amendment
  - Effective: 2023-02-16
  source text: On and effective February 16, 2023, the Board approved and adopted an amendment and restatement of the Company’s second amended and restated bylaws (as so amended and restated, the “Third Amended and Restated Bylaws”), effective as of February 16, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/0001213900-23-012596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.